ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1568

Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis

Hernán Maldonado-Ficco1, Arane Thavaneswaran2, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: joint damage, psoriatic arthritis and tobacco use

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The association between smoking and radiographic progression has been established in axial spondyloarthritides and rheumatoid arthritis (RA) but this association has not been established in psoriatic arthritis (PsA). The aim of this study was to determine the effects of cigarette smoking on clinical joint damage in patients with psoriatic arthritis.

Methods: From 1306 PsA patients followed prospectively between 1978 and 2014 as part of an observational cohort, a total of 1107 that started treatment after the first visit was included in the current study. We defined clinical damage as limitation of movement of more than 20% of the range that is not related to a joint effusion, the presence of flexion contractures, fused or flail joints, or evidence of surgery in a particular joint. We used clinical damage as it is assessed at each protocol visit and we have previously demonstrated that clinical joint damage in linked to radiological joint damage. We evaluated the smoking status at the baseline visit up until the first development of clinical joint damage. Smoking status was defined as ‘non-smoker’, ‘past smoker’ and ‘current smoker’. Time to development of joint damage was assessed using a Cox Regression Analysis to determine the factors predictive of clinical damage, including age, sex, dactylitis and smoking status, joint counts, treatment and HLA B*27 status. 

Results: Among the 1107 patients, 55.6% were males, with a mean age of 46 years, duration of psoriasis 17.4 years and the duration of PsA 8.4 years at baseline. 55.6% of the patients were non-smokers, 24.4% were past-smokers and 12.4% were current smokers. 7.9% of the patient had clinical joint damage and 26% had dactylitis at baseline. Males, HLA-B*27 positivity, higher age at diagnosis of PsA, clinical damage at baseline, dactylitis and swollen joints were associated with a higher probability of developing clinically damaged joints whereas current and past-smokers at baseline were associated with a lower probability of developing clinically damaged joints compared to non-smokers.

Conclusion: Unlike what occurs in RA and ankylosing spondylitis, the clinical damage in PsA was not associated with smoking status but was associated with disease-specific features. 


Disclosure:

H. Maldonado-Ficco,
None;

A. Thavaneswaran,
None;

V. Chandran,
None;

D. D. Gladman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-damage-is-not-associated-with-smoking-status-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology